DYAI

Dyadic International Inc

Add to Watchlist

Advanced Chart

1.130

-0.04(-3.419%)1D

Line

Candle

YTD

High

1.200

Open

1.200

VWAP

1.15

Vol

54.79K

Mkt Cap

40.89M

Low

1.100

Amount

62.74K

EV/EBITDA(TTM)

Total Shares

29.24M

40.86M

EV/OCF(TTM)

P/S(TTM)

8.14

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

1.38M

+68.65%

-0.010

-85.71%

1.12M

-42.64%

-0.037

-26.66%

600.00K

+55.48%

-0.043

+333.3%

Estimates Revision

The market is revising Downward the revenue expectations for Dyadic International, Inc. (DYAI) for FY2025, with the revenue forecasts being adjusted by -11.82% over the past three months. During the same period, the stock price has changed by 11.88%.

Revenue Estimates for FY2025

Revise Downward

-11.82%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+13.24%

In Past 3 Month

Stock Price

Go Up

+11.88%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast DYAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYAI is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.130

Low

5.00

Averages

5.00

High

5.00

Current: 1.130

Low

5.00

Averages

5.00

High

5.00

H.C. Wainwright

Swayampakula Ramakanth

NULL -> Buy

initiated

2025-10-23

Reason

H.C. Wainwright

Swayampakula Ramakanth

Price Target

2025-10-23

initiated

NULL -> Buy

Reason

H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Dyadic International with a Buy rating and $3 price target. The company produces recombinant proteins based on proprietary fungus-based platforms, the analyst tells investors in a research note. The firm is "encouraged" by Dyadic's efforts to expand its platform into further non-pharmaceutical applications and views them as upside to estimates.

Craig-Hallum

Matthew Hewitt

initiated

2025-09-08

Reason

Craig-Hallum

Matthew Hewitt

Price Target

2025-09-08

initiated

Reason

Craig-Hallum analyst Matthew Hewitt initiated coverage of Dyadic International with a Buy rating and $5 price target.

Craig-Hallum

Matthew Hewitt

Buy

initiated

2025-09-08

Reason

Craig-Hallum

Matthew Hewitt

Price Target

2025-09-08

initiated

Buy

Reason

As previously reportedly. Craig-Hallum analyst Matthew Hewitt initiated coverage of Dyadic International with a Buy rating and $5 price target. The firm likes the overlap of the multiple near-term catalysts from the commercialization of their portfolio. Moreover, Craig-Hallum sees the possibility of substantial gains from partners advancing Dyadic's proprietary platforms through their clinical research. With shares currently trading at a multiple of 2.7-times EV to FY26 sales, a discount to peers, the firm thinks the current valuation offers an attractive entry point for investors.

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2024-11-14

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2024-11-14

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Dyadic International Inc (DYAI.O) is -8.37, compared to its 5-year average forward P/E of -10.08. For a more detailed relative valuation and DCF analysis to assess Dyadic International Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.08

Current PE

-8.37

Overvalued PE

-4.81

Undervalued PE

-15.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.45

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

5.63

Undervalued EV/EBITDA

-12.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

15.03

Current PS

1.13

Overvalued PS

29.26

Undervalued PS

0.80